JPRN-UMIN000009374已完成1 期
Haploidentical hematopoietic stem cell transplantation in combination with posttransplant cyclophosphamide and ATG-thymoglobulin Phase I study - Post-CY haploHSCT with ATG (MAC)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 55years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Organ dysfunction (2) Uncontrolled hypertension (3) HIV positive (4) Uncontrolled active infection (5) Uncontrolled CNS invasion (6) Pregnant (7) Psychiatric disorder (8) Allergy to drugs used for HSCT (9) Other reason which physicians think the patient is inappropriate for the study
研究者
相似试验
已完成
1 期
Haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide in combination with thymoglobulin (RIC version) Phase IHematological malignancyJPRN-UMIN000011004ational Cancer Center Hospital12
已完成
2 期
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1HIRCT138706061030N2Tehran University of Medical Sciences10
已完成
不适用
Allogeneic hematopoietic stem cell transplantation for elderly patientsJPRN-UMIN000017744nivesity of Tokyo Hospital, Department of Hematology and Oncology50
已完成
不适用
Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-haploidentical related donor using reduced dose of posttransplantation high-dose cyclophosphamide (PTCy) for poor prognosis or refractory hematological malignancies (OCU16-2)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia(ALL) Acute leukemias of ambiguous lineage Myelodysplastic syndrome(MDS) Chronic myeloid leukemia(CML) Adult T-cell leukemia/lymphoma(ATLL) Malignant lymphoma(ML)JPRN-UMIN000026028Osaka City University33
招募中
2 期
Allogeneic hematopoietic stem cell transplantation from HLA6/8-4/8 matched related donor for poor prognostic or refractory hematologic malignancy and solid tumor - Ibaraki Children's Hospital phase II studyAcute leukemia, malignant lymphoma, and solid tumorJPRN-UMIN000027010Ibaraki Children's Hospital30